Clements Ian
Known title: Chief Financial OfficerCIK: 0001780080
Clements Ian's purchase track record
Clements Ian has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2021 | MIRM | $21K | +67.1% | +79.5% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MIRM | ▲ Buy | Grant | 325 | $6K | 11/10/2022 | View on chart |
| MIRM | ▲ Buy | Grant | 1,125 | $15K | 5/10/2022 | View on chart |
| MIRM | ▲ Buy | Grant | 10,000 | $0 | 1/6/2022 | View on chart |
| MIRM | ▲ Buy | Open Market | 750 | $10K | 11/26/2021 | View on chart |
| MIRM | ▲ Buy | Open Market | 700 | $10K | 11/24/2021 | View on chart |
| MIRM | ▲ Buy | Grant | 458 | $6K | 11/10/2021 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,574 | $30K | 10/1/2021 | View on chart |
| MIRM | ▲ Buy | Grant | 9,375 | $0 | 9/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.